SANGAMO THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Alexander D. Macrae, M.B., Ch.B., Ph.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alexander D. Macrae, M.B., Ch.B., Ph.D.”): 102,677,999 for, 13,424,026 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Courtney Beers, Ph.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Courtney Beers, PhD.”): 104,443,777 for, 11,180,653 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: H. Stewart Parker

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: H. Stewart Parker”): 91,662,087 for, 23,918,287 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 40,622,694 for, 1,685,299 against, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: James R. Meyers

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: James R. Meyers”): 103,985,480 for, 11,583,362 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: John H. Markels, Ph.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: John H. Markels, Ph.D.”): 102,086,569 for, 13,568,224 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 41,627,191 for, 680,802 against, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Karen L. Smith, M.D., Ph.D., M.B.A, L.L.M.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.”): 104,262,373 for, 11,342,802 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Kenneth J. Hillan, M.B., Ch.B.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kenneth J. Hillan, M.B.”): 104,440,267 for, 11,196,089 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Margaret A. Horn, J.D.

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Margaret A. Horn, J.D.”): 108,722,555 for, 6,881,692 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 41,681,702 for, 626,291 against, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To elect the nine nominees for director, named below, to serve on the Board of Directors until the next annual meeting of stockholders to be held in 2025 and until their successors are duly elected and qualified: Robert F. Carey

SANGAMO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert F. Carey”): 109,721,890 for, 5,869,313 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors: Each of the nominees for director listed in the Proxy Statement was elected by the votes set forth below:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To approve an amendment of our Seventh Amended and Restated Certificate of Incorporation, as amended, or the Restated Certificate, to increase the total number of shares of our common stock authorized for issuance from 640,000,000 to 960,000,000 shares;

SANGAMO THERAPEUTICS INC.’s own tally for this item (“4. Approval of Amendment to Restated Certificate to Increase Authorized Number of Shares of Common Stock”): 107,950,334 for, 8,623,071 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 41,886,505 for, 440,003 against.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To approve the amendment and restatement of the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan, or the 2018 Plan, to, among other things, increase the aggregate number of shares of our common stock reserved for issuance under the 2018 Plan by 11,000,000 shares;

SANGAMO THERAPEUTICS INC.’s own tally for this item (“3. Approval of the Amended 2018 Plan”): 107,523,557 for, 8,902,456 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,105,620 for, 202,373 against, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, or NEOs, as described in the accompanying Proxy Statement;

SANGAMO THERAPEUTICS INC.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Named Executive Officers as Disclosed in the Proxy Statement”): 101,303,168 for, 15,057,209 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 42,197,134 for, 110,859 against, 18,515 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 110 managers: 63,897,231 for, 691,919 against, 75,000 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024

SANGAMO THERAPEUTICS INC.’s own tally for this item (“5. Ratification of Appointment of Independent Registered Public Accounting Firm”): 151,112,572 for, 4,145,949 against, per its Form 8-K filed June 5, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 42,307,993 for, 18,515 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.